At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 20 target
Drug / intervention
Proton Stereotactic Body Radiation therapy (SBRT)radiation
Likely dose
Not stated in record
Key inclusion· 5
- ✓Age 18 years or older
- ✓Biopsy-confirmed renal cell carcinoma
- ✓No metastatic disease on clinical or radiographic evaluation
- ✓Not a candidate for surgery or local ablative procedures
Key exclusion· 3
- ✕Prior radiation therapy with overlapping treatment fields
- ✕Proven metastatic disease
- ✕Pregnant or planning pregnancy during treatment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Apr 19, 2024·Updated Apr 3, 2026
In Brief
A Phase 2 clinical trial evaluating Proton Stereotactic Body Radiation therapy (SBRT) for Renal Cell Carcinoma. Currently recruiting, targeting 20 participants across 1 site.
Detailed Summary
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
CollaboratorsRobert L. Sloan Fund for Cancer Research
Timeline
Phase 2Recruiting
202520262027202820292030
First PostedApr 2024
Enrollment StartFeb 2025
TodayJul 2026
Primary CompletionJun 2027
Study CompletionAug 2030
First PostedApr 19, 2024
Enrollment StartFeb 25, 2025
Primary CompletionJun 1, 2027
Study CompletionAug 1, 2030
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 2.2 years agoPrimary completion in 11 months
Interventions
Proton Stereotactic Body Radiation therapy (SBRT)radiation
Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks